Search

Your search keyword '"Kambiz, Rahbar"' showing total 4 results
Start Over Author "Kambiz, Rahbar" Publisher mdpi ag
4 results on '"Kambiz, Rahbar"'

1. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis

Author

Finn Edler von Eyben, Glenn Bauman, Rie von Eyben, Kambiz Rahbar, Cigdem Soydal, Alexander R. Haug, Irene Virgolini, Harshad Kulkarni, Richard Baum, and Giovanni Paganelli

Subjects
adverse effects, decline of prostate specific antigen, metastases, overall survival, predictive factors, prostate cancer, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract

The aim of the review was to evaluate patient and treatment characteristics for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand therapy (PRLT) associated with above-average outcome. The systematic review and meta-analysis followed recommendations by the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA). We searched for publications in PubMed, Embase, and ClinicalTrials.gov up to 31 September 2020. Thirty-six publications and four duplicates reported 2346 patients. Nearly two-thirds of the patients had bone metastases. Median overall survival (OS) was 16 months. Asymptomatic patients and patients with only lymph node metastases lived longer than symptomatic patients and patients with more extensive metastases. Patients treated with an intensified schedule of 177Lu PRLT lived longer than those treated with a conventional schedule. Half of the patients obtained a PSA decline ≥ 50% and these patients lived longer than those with less PSA decline. Approximately 10% of the patients developed hematologic toxicity with anemia grade 3 as the most severe adverse effect. Characteristics for patients, cancer, restaging, and PRLT predict above average overall survival following treatment with PRLT.

Published
2020
Full Text
View/download PDF

2. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone

Author

Martin Boegemann, Katrin Schlack, Stefan Thomes, Julie Steinestel, Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Aringer, and Laura-Maria Krabbe

Subjects
neutrophil-to-lymphocyte ratio, castration-resistant prostate cancer, prognostic biomarker, treatment response, abiraterone, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract

The purpose of this study was to examine the prognostic capability of baseline neutrophil-to-lymphocyte-ratio (NLR) and NLR-change under Abiraterone in metastatic castration-resistant prostate cancer patients. The impact of baseline NLR and change after eight weeks of treatment on progression-free survival (PFS) and overall survival (OS) was analyzed using Kaplan-Meier-estimates and Cox-regression. 79 men with baseline NLR 5 were analyzed. In baseline analysis of PFS NLR >5 was associated with non-significantly shorter median PFS (five versus 10 months) (HR: 1.6 (95%CI:0.9–2.8); p = 0.11). After multivariate adjustment (MVA), ECOG > 0–1, baseline LDH>upper limit of normal (UNL) and presence of visceral metastases were independent prognosticators. For OS, NLR >5 was associated with shorter survival (seven versus 19 months) (HR: 2.3 (95%CI:1.3–4.0); p < 0.01). In MVA, ECOG > 0–1 and baseline LDH > UNL remained independent prognosticators. After 8 weeks of Abiraterone NLR-change to 5, NLR-change to

Published
2017
Full Text
View/download PDF

3. The Role of Neuroaxis Irradiation in the Treatment of Intraspinal Ewing Sarcoma: A Review and Meta-Analysis

Author

Fabian M. Troschel, Kai Kröger, Jan J. Siats, Kambiz Rahbar, Hans Theodor Eich, and Sergiu Scobioala

Subjects
Cancer Research, Oncology
Abstract

The role of cranio-spinal irradiation (CSI) for primary extraosseous intraspinal Ewing sarcoma (EwS) remains unclear. Here, we evaluate clinical and survival outcomes in patients with primary intraspinal EwS treated with CSI as part of multimodal primary therapy regimens. We abstracted patient information, including details on treatment application, efficacy, and tolerance from the literature and our hospital database for a cohort of 24 primary intraspinal EwS patients treated with CSI. Median age was 25.5 years, median CSI dose was 36 Gy and mean boost dose was 12.8 Gy. Sixteen patients (66.7%) achieved complete radiological remission, another 5 patients demonstrated partial response and 1 patient showed no response to treatment. Compared to a cohort of patients treated with focal radiotherapy, CSI patients were more likely to have multifocal disease at time of diagnosis (p = 0.001) and intradural tumor location (p < 0.001). Despite over-representation of these unfavorable characteristics, there was no survival difference between groups (p = 0.58). While CSI shows promising results in the treatment of primary intraspinal EwS, treatment should be considered individually based on tumor and patient characteristics in the absence of prospective trials.

Published
2022

4. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone

Author

Stefan Thomes, Axel Semjonow, Laura-Maria Krabbe, Martin Boegemann, Kambiz Rahbar, Andres J. Schrader, Martin Aringer, Julie Steinestel, and Katrin Schlack

Subjects
Male, Oncology, Neutrophils, 030232 urology & nephrology, Kaplan-Meier Estimate, lcsh:Chemistry, Leukocyte Count, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, abiraterone, castration-resistant prostate cancer, Lymphocytes, Neoplasm Metastasis, neutrophil-to-lymphocyte ratio, prognostic biomarker, treatment response, lcsh:QH301-705.5, Spectroscopy, General Medicine, Middle Aged, Prognosis, Computer Science Applications, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, 030220 oncology & carcinogenesis, Androstenes, medicine.medical_specialty, Antineoplastic Agents, Castration resistant, Article, Catalysis, Inorganic Chemistry, 03 medical and health sciences, Internal medicine, medicine, Overall survival, Humans, In patient, Physical and Theoretical Chemistry, Neutrophil to lymphocyte ratio, Molecular Biology, Aged, Proportional Hazards Models, business.industry, Organic Chemistry, fungi, medicine.disease, Surgery, Abiraterone, chemistry, lcsh:Biology (General), lcsh:QD1-999, business
Abstract

The purpose of this study was to examine the prognostic capability of baseline neutrophil-to-lymphocyte-ratio (NLR) and NLR-change under Abiraterone in metastatic castration-resistant prostate cancer patients. The impact of baseline NLR and change after eight weeks of treatment on progression-free survival (PFS) and overall survival (OS) was analyzed using Kaplan-Meier-estimates and Cox-regression. 79 men with baseline NLR 5 were analyzed. In baseline analysis of PFS NLR >5 was associated with non-significantly shorter median PFS (five versus 10 months) (HR: 1.6 (95%CI:0.9–2.8); p = 0.11). After multivariate adjustment (MVA), ECOG > 0–1, baseline LDH>upper limit of normal (UNL) and presence of visceral metastases were independent prognosticators. For OS, NLR >5 was associated with shorter survival (seven versus 19 months) (HR: 2.3 (95%CI:1.3–4.0); p < 0.01). In MVA, ECOG > 0–1 and baseline LDH > UNL remained independent prognosticators. After 8 weeks of Abiraterone NLR-change to 5, NLR-change to

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results